Metropolis Healthcare - Soft Quarter; Outlook Remains Promising
MHL’s Q3FY25 EBITDA missed street/our estimates by 9%/4%, with revenue growing 11% YoY driven by B2C revenue improving 15% YoY.
435 Views
Metropolis Healthcare - Growth Levers Adequately in Place
Metropolis’ Q3FY25 result was impacted by lower sales from institutional biz (2% impact on revenue) and muted growth in acute ailment tests.
409 Views
Metropolis Healthcare - Inorganic Foray into Non-Core Markets; Scalability Key Monitorable
MHL announced its acquisition of Core Diagnostics—an oncology focused diagnostics chain with majority of its revenue derived from North/East India—...
320 Views
Metropolis Healthcare: Core Diagnostic M&A to Strengthen Speciality Portfolio.
Metropolis signed a definite agreement to acquire a 100% stake in Core Diagnostics. This acquisition will strengthen its advanced cancer testing...
453 Views
Metropolis Healthcare - Tier 3 Expansion and Wellness Portfolio to Drive Revenue Growth
MHL’s Q2FY25 print was in line with our estimates, with revenues growing 13% YoY, driven by B2C revenues improving 21% YoY.
233 Views